{"id":496151,"date":"2020-07-15T14:52:02","date_gmt":"2020-07-15T14:52:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=496151"},"modified":"2020-07-15T14:52:02","modified_gmt":"2020-07-15T14:52:02","slug":"fibrodysplasia-ossificans-progressiva-fop-companies-assessment-report-emerging-drugs-and-competitive-landscape","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/fibrodysplasia-ossificans-progressiva-fop-companies-assessment-report-emerging-drugs-and-competitive-landscape_496151.html","title":{"rendered":"Fibrodysplasia Ossificans Progressiva (FOP) Companies Assessment Report, Emerging drugs and Competitive landscape"},"content":{"rendered":"
\"Fibrodysplasia<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
“Fibrodysplasia Ossificans Progressiva (FOP) Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Fibrodysplasia Ossificans Progressiva (FOP) market. A detailed picture of the Fibrodysplasia Ossificans Progressiva (FOP) pipeline landscape is provided, which includes the disease overview and Fibrodysplasia Ossificans Progressiva (FOP) treatment guidelines. <\/div>\n

Fibrodysplasia ossificans progressiva (FOP) <\/strong>is a disorder in which muscle and connective tissue such as tendons and ligaments are gradually replaced by bone (ossified), forming bone outside the skeleton (extra-skeletal or heterotopic bone) that constrains movement. This process generally becomes noticeable in early childhood, starting with the neck and shoulders, and proceeding down the body and into the limbs. Mutations in the ACVR1 gene causes fibrodysplasia ossificans progressiva. The underlying genetic mutation in FOP alters the signals that regulate the induction of cell differentiation leading to bone formation.<\/p>\n

The symptoms begin in the first decade of life with episodes of painful inflammatory soft tissue swellings. Gradually, there occurs restriction of motion at various joints, severely limiting the activities of daily living and the quality of life of such patients by the third decade of life. <\/p>\n

\"\"<\/p>\n

“Fibrodysplasia Ossificans Progressiva (FOP) Pipeline Insight, 2020<\/strong><\/a>” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Fibrodysplasia Ossificans Progressiva (FOP) market. A detailed picture of the Fibrodysplasia Ossificans Progressiva (FOP) pipeline landscape is provided, which includes the disease overview and Fibrodysplasia Ossificans Progressiva (FOP) treatment guidelines.<\/p>\n

The assessment part of the report embraces in-depth Fibrodysplasia Ossificans Progressiva (FOP) commercial assessment and clinical assessment of the Fibrodysplasia Ossificans Progressiva (FOP) pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Fibrodysplasia Ossificans Progressiva (FOP) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n

View report: https:\/\/www.delveinsight.com\/report-store\/fibrodysplasia-ossificans-progressiva-fop-pipeline-insight<\/a><\/strong><\/p>\n

Pipeline development activities: Fibrodysplasia Ossificans Progressiva (FOP) <\/strong><\/p>\n

The report provides insights into: 
1. All of the companies that are developing therapies for the treatment of Fibrodysplasia Ossificans Progressiva (FOP) with aggregate therapies developed by each company for the same.
2. Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Fibrodysplasia Ossificans Progressiva (FOP) treatment.
3. Fibrodysplasia Ossificans Progressiva (FOP) key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
4. Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
5. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Fibrodysplasia Ossificans Progressiva (FOP) market.<\/p>\n

The report is built using data and information traced from the researcher’s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university web sites and industry-specific third-party sources, etc. <\/p>\n

Request for sample pages:https:\/\/www.delveinsight.com\/sample-request\/fibrodysplasia-ossificans-progressiva-fop-pipeline-insight<\/a><\/strong><\/p>\n

The key players in Fibrodysplasia Ossificans Progressiva market are:<\/strong>
1. Ipsen
2. Regeneron Pharmaceuticals
3. BioCryst
4. Keros Therapeutics
and many others <\/p>\n

The launch of the emerging therapies is expected to significantly impact Fibrodysplasia Ossificans Progressiva treatment scenario in the upcoming years:-<\/strong>
Drugs covered<\/strong>
1. Palovarotene
2. Garetosmab (REGN2477)
3. BLU-782
4. BCX9250
5. KER-047
and many others<\/p>\n

Scope of the report:<\/strong><\/p>\n

1. The Fibrodysplasia Ossificans Progressiva (FOP) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Fibrodysplasia Ossificans Progressiva (FOP) across the complete product development cycle, including all clinical and non-clinical stages.
2. It comprises of detailed profiles of Fibrodysplasia Ossificans Progressiva (FOP) therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
3. Detailed Fibrodysplasia Ossificans Progressiva (FOP) research and development progress and trial details, results wherever available, are also included in the pipeline study.
4. Coverage of dormant and discontinued pipeline projects along with the reasons if available across Fibrodysplasia Ossificans Progressiva (FOP).<\/p>\n

Table of contents:<\/strong><\/p>\n

1. Report Introduction
2. Fibrodysplasia Ossificans Progressiva (FOP) 
3. Fibrodysplasia Ossificans Progressiva (FOP) Current Treatment Patterns
4. Fibrodysplasia Ossificans Progressiva (FOP) – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Fibrodysplasia Ossificans Progressiva (FOP) Late Stage Products (Phase-III)
7. Fibrodysplasia Ossificans Progressiva (FOP) Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Fibrodysplasia Ossificans Progressiva (FOP) Discontinued Products
13. Fibrodysplasia Ossificans Progressiva (FOP) Product Profiles
14. Fibrodysplasia Ossificans Progressiva (FOP) Key Companies
15. Fibrodysplasia Ossificans Progressiva (FOP) Key Products
16. Dormant and Discontinued Products
17. Fibrodysplasia Ossificans Progressiva (FOP) Unmet Needs
18. Fibrodysplasia Ossificans Progressiva (FOP) Future Perspectives
19. Fibrodysplasia Ossificans Progressiva (FOP) Analyst Review  
20. Appendix
21. Report Methodology<\/p>\n

Download report: https:\/\/www.delveinsight.com\/sample-request\/fibrodysplasia-ossificans-progressiva-fop-pipeline-insight<\/a><\/strong><\/p>\n

About DelveInsight:<\/strong><\/p>\n

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/p>\n

 <\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP “Fibrodysplasia Ossificans Progressiva (FOP) Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Fibrodysplasia Ossificans Progressiva (FOP) market. A detailed picture of the Fibrodysplasia Ossificans Progressiva … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,404],"tags":[],"class_list":["post-496151","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/496151","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=496151"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/496151\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=496151"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=496151"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=496151"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}